TrialAnnals of the rheumatic diseases2015

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

Yoshiya Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.